LRB-1785/P2
TJD:cdc
2019 - 2020 LEGISLATURE
DOA:......Bollhorst, BB0270 - Methadone use in opioid and methamphetamine treatment programs
For 2019-2021 Budget -- Not Ready For Introduction
An Act ...; relating to: the budget.
Analysis by the Legislative Reference Bureau
health and human services
Mental illness and developmental disabilities
1. Methadone use in opioid treatment programs
Under current law, DHS is required to create two or three comprehensive opioid treatment programs and two or three additional opioid and methamphetamine treatment programs to provide treatment for opioid, opiate, and methamphetamine addiction in underserved, high-need areas. The programs must provide counseling, medication-assisted treatment, and abstinence-based treatment. Current law prohibits these treatment programs from offering methadone treatment, and this bill removes that prohibition.
The people of the state of Wisconsin, represented in senate and assembly, do enact as follows:
Section
1. 51.422 (1) of the statutes is amended to read:
51.422 (1) Program creation. The department shall create 2 or 3 new, regional comprehensive opioid treatment programs, and in the 2017-19 fiscal biennium, shall create 2 or 3 additional regional comprehensive opioid and methamphetamine treatment programs, to provide treatment for opioid and opiate addiction and methamphetamine addiction in underserved, high-need areas. The department shall obtain and review proposals for opioid and methamphetamine treatment programs in accordance with its request-for-proposal procedures. A program under this section may not offer methadone treatment.
Section 2
. 51.422 (2) of the statutes is amended to read:
51.422 (2) Program components. An opioid or methamphetamine treatment program created under this section shall offer an assessment to individuals in need of service to determine what type of treatment is needed. The program shall transition individuals to a certified residential program, if that level of treatment is necessary. The program shall provide counseling, medication-assisted treatment, including both long-acting opioid antagonist and partial agonist medications that have been approved by the federal food and drug administration if for treating opioid addiction, and abstinence-based treatment. The program shall transition individuals who have completed treatment to county-based or private post-treatment care.
(End)
